

## ORAL COMMUNICATIONS

WEDNESDAY, 11 JULY 2007

15:45 - 17:15

- O-W-064 **A HIGHLY-SENSITIVE PLASMA VON WILLEBRAND FACTOR (VWF): RISTOCETIN COFACTOR ACTIVITY ASSAY BY FLOW CYTOMETRY**  
D. Chen\* (US), R. K. Pruthi, W. L. Nichols, J. A. Heit, W. G. Owen 16:30 - 16:45
- O-W-065 **A COMMON LARGE DELETION OF VWF IN GERMAN AND ITALIAN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE TYPE 3**  
R. Schneppenheim\* (DE), G. Castaman, A. B. Federici, M. Franchini, W. Kreuz, R. Marschalek, J. Oldenburg, T. Obser, F. Oyen, U. Budde 16:45 - 17:00
- O-W-066 **THE INFLUENCE OF INTRON 1 SEQUENCE VARIATIONS IN MUTATION-NEGATIVE TYPE 1 VON WILLEBRAND DISEASE PATIENTS**  
M. Othman\* (CA), Y. Chirinian, C. Brown, D. Lillicrap 17:00 - 17:15

### New anticoagulants

Room C

Chairpersons: *R. Bauersachs (DE), B. I. Eriksson (SE)*

- O-W-049 **DABIGATRAN ETEXILATE IS EFFECTIVE AND SAFE FOR THE EXTENDED PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP REPLACEMENT**  
B. I. Eriksson\* (SE), O. E. Dahl, N. Rosencher, A. A. Kurth, N. V. Dijk, S. P. Frosticks, R. Hettiarachchi, S. Hantel, J. Schnee, H. R. Büller 15:45 - 16:00
- O-W-050 **THE ORAL DIRECT THROMBIN INHIBITOR, DABIGATRAN ETEXILATE, IS EFFECTIVE AND SAFE FOR PREVENTION OF MAJOR VENOUS THROMBOEMBOLISM FOLLOWING MAJOR ORTHOPEDIC SURGERY**  
J. A. Caprini\* (US), E. Hwang, S. Hantel, J. Schnee, B. I. Eriksson 16:00 - 16:15
- O-W-051 **DABIGATRAN ETEXILATE VERSUS ENOXAPARIN IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING TOTAL KNEE ARTHROPLASTY**  
R. J. Friedman\* (US), J. A. Caprini, P. C. Comp, B. L. Davidson, C. W. Francis, J. Ginsberg, M. Huo, J. Lieberman, J. E. Muntz, G. E. Raskob, M. L. Clements, S. Hantel, J. Schnee 16:15 - 16:30
- O-W-052 **TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS (DVT): RIVAROXABAN ONCE OR TWICE DAILY HAD SIMILAR EFFICACY AND SAFETY TO STANDARD THERAPY IN PHASE II STUDIES**  
H. R. Büller\* (NL), G. Agnelli 16:30 - 16:45
- O-W-053 **SAFETY AND TOLERABILITY OF THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 IN PREVENTION OF STROKE AND OTHER THROMBOEMBOLIC COMPLICATIONS ASSOCIATED WITH ATRIAL FIBRILLATION (AF)**  
B. Olsson\* (SE), L. H. Rasmussen, A. Tveit, E. Jensen, P. Wessman, S. Panfilov, H. D. Ekdal, K. Wählander 16:45 - 17:00
- O-W-054 **ONCE-WEEKLY SUBCUTANEOUS IDRAPARINUX (ANTI-XA) VERSUS ORAL VITAMIN K ANTAGONIST THERAPY FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION**  
H. Büller\* (NL) for the AMADEUS Investigators 17:00 - 17:15